Austria-based Hoopika has landed $10 million to back development of its platform vaccine technology and fund early-stage trials of the company's lead drug. Sofinnova Partners led the round, with help from Forbion Capital Partners.
Hoopkia is developing preventative and therapeutic vaccines using its Vaxwave platform technology, which the company says offers long-lasting and potent stimulation of both cellular and humoral immunity. The funding will support development of the Hoopika's lead product candidate, HB101, through preclinical development and a Phase I proof of concept study, and to further develop the company's Vaxwave technology.
“Effective vaccines inducing a potent combination of cellular and humoral immunity represent the next frontier in vaccinology," Sofinnova partner Graziano Seghezzi in a statement. "Hookipa’s Vaxwav technology addresses the industry’s current shortcomings, potentially paving the way for the treatment of numerous persistent viral infections. Sofinnova Partners will bring its expertise and open its network to the company; and I am thrilled to work alongside Katherine Cohen in building Hookipa Biotech’s success."
- check out the release